Remiges Ventures
2022.06.06Luca Science, one of our portfolio companies in Japan, closed a $30.3M Series B round
2022.06.02Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168
2022.03.08Digestome Therapeutics announced first patient enrolled in Phase1 clinical trial of DGX-001
2022.01.10The Inflectis Bioscience received approval from French regulatory authority to conduct a Phase 2 Clinical Trial for IFB-088 for ALS
2021.06.23Remiges joined Series B Round of Glycomine in California
2021.05.27The core technology of Imel BioTherapeutics, Inc. was published in Scientific Reports
